ALL MARKETS
FTSE 100
FTSE 250
AIM MARKET


Shield Therapeutics.
63 announcements.
Time Ticker Company Announcement
09:13 STX Hardman & Co Research
Shield Therapeutics (STX): FDA approval ushers in a new era for Shield
07:00 STX Shield Therapeutics
Investor presentations
10:17 STX Shield Therapeutics
Director/PDMR Shareholding
07:00 STX Shield Therapeutics
Half-year Report
11:22 STX Hardman & Co Research
Shield Therapeutics (STX) FDA approval opens door to major US opportunity
13:21 STX Shield Therapeutics
Notice of Results
14:05 STX Shield Therapeutics
Second Price Monitoring Extn
14:00 STX Shield Therapeutics
Price Monitoring Extension
07:00 STX Shield Therapeutics
FDA approves Feraccru� with a broad label
12:00 STX Shield Therapeutics
Additional Listing
14:16 STX Shield Therapeutics
Result of AGM
07:00 STX Shield Therapeutics
Update on Legal Proceedings
12:00 STX Hardman & Co Research
Shield Therapeutics (STX): All in the execution
07:00 STX Shield Therapeutics
Appointment of Joint Broker
07:00 STX Shield Therapeutics
Investor presentation
11:58 STX Shield Therapeutics
Additional Listing
07:00 STX Shield Therapeutics
2018 Annual Report and 2019 AGM Notice
07:00 STX Shield Therapeutics
Major extension to approval in Switzerland
15:42 STX Shield Therapeutics
Additional Listing
07:00 STX Shield Therapeutics
Final Results
12:00 STX Shield Therapeutics
Change of Adviser
07:00 STX Shield Therapeutics
Notice of Results
15:31 STX Shield Therapeutics
Positive decision on Feraccru�'s process patent
07:00 STX Shield Therapeutics
Positive results for Feraccru� in AEGIS-H2H study
07:00 STX Shield Therapeutics
Positive results of AEGIS-CKD study
07:15 STX Hardman & Co Research
Shield Therapeutics (STX): Cast-iron investment
07:00 STX Shield Therapeutics
Business and trading update
10:19 STX Shield Therapeutics
Investor presentations
07:00 STX Shield Therapeutics
Appointment of Chairman
07:00 STX Shield Therapeutics
US New Drug Application PDUFA date for Feraccru
10:04 STX Shield Therapeutics
UK launch of Feraccru� by Norgine
07:00 STX Shield Therapeutics
New Drug Application for Feraccru�
15:46 STX Shield Therapeutics
Holding(s) in Company
13:54 STX Shield Therapeutics
Notification Of Major Holdings
07:00 STX Shield Therapeutics
Submission of an NDA for Feraccru� with the FDA
13:02 STX Shield Therapeutics
Holding(s) in Company
13:06 STX Shield Therapeutics
Director/PDMR Shareholding
07:14 STX Shield Therapeutics
Licence for the commercialisation of Feraccru
07:12 STX Shield Therapeutics
Interim Results
07:00 STX Shield Therapeutics
AEGIS-H2H Completion of Recruitment
07:00 STX Shield Therapeutics
Appointment of Non-Executive Director
07:00 STX Shield Therapeutics
Business Update
16:27 STX Shield Therapeutics
Holdings in Company
16:26 STX Shield Therapeutics
Holdings in Company
11:56 STX Shield Therapeutics
Result of AGM
07:00 STX Shield Therapeutics
Data from real-world clinical use of Feraccru
07:00 STX Shield Therapeutics
Positive top-line results from AEGIS-PAED PK study
07:00 STX Shield Therapeutics
Directorate Change
07:00 STX Shield Therapeutics
2017 Annual Report and 2018 AGM Notice
07:00 STX Shield Therapeutics
Grant of share options
07:00 STX Shield Therapeutics
Notice of Results
07:00 STX Shield Therapeutics
Top-line results from Feraccru Phase III study
07:00 STX Shield Therapeutics
Business and Trading Update
13:56 STX Shield Therapeutics
Receives CHMP positive opinion on Feraccru�
07:00 STX Shield Therapeutics
Update on the AEGIS-CKD study
07:00 STX Shield Therapeutics
Broadening of Feraccru indication
07:00 STX Shield Therapeutics
Appointment of Non-Executive Director
07:00 STX Shield Therapeutics
Results of Pre-Submission Meeting with FDA
07:00 STX Shield Therapeutics
Preliminary Results for the Year Ended 31 Dec 17
11:00 STX Shield Therapeutics
Price Monitoring Extension
17:26 STX Shield Therapeutics
Holding(s) in Company
09:20 STX Shield Therapeutics
Holding(s) in Company
18:21 STX Shield Therapeutics
Grant of share options